The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

NCT00444912 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma
Hodgkin Disease

Interventions

DRUG: G-CSF plus plerixafor
DRUG: G-CSF plus plerixafor
BIOLOGICAL: rituximab

Sponsor

Genzyme, a Sanofi Company